Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study

Proton pump inhibitors (PPIs) are widely used for the treatment of acid‐related diseases. Vonoprazan is a member of a new class of acid suppressants; potassium‐competitive acid blockers. Vonoprazan may thus be an alternative to PPIs.

[1]  N. Hiramatsu,et al.  Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis , 2015, Alimentary pharmacology & therapeutics.

[2]  R. Jenkins,et al.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects , 2015, Clinical and Translational Gastroenterology.

[3]  R. Jenkins,et al.  Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects , 2015, Alimentary pharmacology & therapeutics.

[4]  H. Blume,et al.  Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update , 2014, Drug Safety.

[5]  Ronald D Lee,et al.  A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. , 2012, Journal of the American College of Cardiology.

[6]  A. Ohnishi,et al.  Dose–response relationships of rabeprazole 5, 10, 20, and 40 mg once daily on suppression of gastric acid secretion through the night in healthy Japanese individuals with different CYP2C19 genotypes , 2011, European Journal of Clinical Pharmacology.

[7]  G. Sachs,et al.  Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438) , 2011, Journal of Pharmacology and Experimental Therapeutics.

[8]  M. Kajino,et al.  A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals , 2011, Journal of Pharmacology and Experimental Therapeutics.

[9]  M. Kajino,et al.  A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. , 2011, Biochemical pharmacology.

[10]  M. Kajino,et al.  1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases , 2010, Journal of Pharmacology and Experimental Therapeutics.

[11]  W. Kraft,et al.  Acid peptic diseases: pharmacological approach to treatment , 2009, Expert review of clinical pharmacology.

[12]  D. Graham,et al.  New concepts of resistance in the treatment of Helicobacter pylori infections , 2008, Nature Clinical Practice Gastroenterology &Hepatology.

[13]  T. Ishizaki,et al.  CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. , 2007, Pharmacogenomics.

[14]  H. Mieno,et al.  Acid‐suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: A crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 , 2006, Clinical pharmacology and therapeutics.

[15]  E. Carlsson,et al.  Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. , 2005, Pharmacology & therapeutics.

[16]  R. Fass,et al.  Systematic review: proton‐pump inhibitor failure in gastro‐oesophageal reflux disease – where next? , 2005, Alimentary pharmacology & therapeutics.

[17]  M. Robinson.  Proton pump inhibitors: update on their role in acid‐related gastrointestinal diseases , 2005, International journal of clinical practice.

[18]  T. Ishizaki,et al.  Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. , 2005, Drug metabolism and pharmacokinetics.

[19]  P. Malfertheiner,et al.  Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia , 2003, Alimentary pharmacology & therapeutics.

[20]  V. Savarino,et al.  Effective intra‐oesophageal acid suppression in patients with gastro‐oesophageal reflux disease: lansoprazole vs. pantoprazole , 2003, Alimentary pharmacology & therapeutics.

[21]  K. Ogawa,et al.  Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers , 2002, Alimentary pharmacology & therapeutics.

[22]  D. Y. Graham.  Critical Effect of Helicobacter pylori Infection on the Effectiveness of Omeprazole for Prevention of Gastric or Duodenal Ulcers Among Chronic NSAID Users , 2002, Helicobacter.

[23]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.

[24]  G. Sachs,et al.  The control of gastric acid and Helicobacter pylori eradication , 2000 .

[25]  S. Ishihara,et al.  CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole , 2000, Alimentary pharmacology & therapeutics.

[26]  G. Sachs,et al.  Review article: the control of gastric acid and Helicobacter pylori eradication. , 2000, Alimentary pharmacology & therapeutics.

[27]  D. Castell,et al.  Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors , 1998, American Journal of Gastroenterology.